Inactivation of bradykinin by angiotensin-converting enzyme and by carboxypeptidase N in human plasma.

@article{Kuoppala2000InactivationOB,
  title={Inactivation of bradykinin by angiotensin-converting enzyme and by carboxypeptidase N in human plasma.},
  author={Antti Kuoppala and Ken A. Lindstedt and Juhani Saarinen and Petri T. Kovanen and Jorma O. Kokkonen},
  journal={American journal of physiology. Heart and circulatory physiology},
  year={2000},
  volume={278 4},
  pages={
          H1069-74
        }
}
Because bradykinin (BK) appears to have cardioprotective effects ranging from improved hemodynamics to antiproliferative effects, inhibition of BK-degrading enzymes should potentiate such actions. The purpose of this study was to find out which enzymes are responsible for the degradation of BK in human plasma. Human plasma from healthy donors (n = 10) was incubated with BK in the presence or absence of specific enzyme inhibitors. At high (micromolar) concentrations, BK was mostly (>90… Expand
Pathways of bradykinin degradation in blood and plasma of normotensive and hypertensive rats.
TLDR
The identical conditions ofKinin degradation in WKY and SHR suggest no pathogenic role of kininases in the SHR model of genetic hypertension, and kinin metabolites were measured by high-performance liquid chromatography. Expand
Kinin-degrading pathways in the human heart.
In experimental animals, kinins protect the myocardium from ischemia-reperfusion injuries and reduce left ventricular hypertrophy and progression of heart failure. This suggests that in humans, also,Expand
Carboxypeptidase B and other kininases of the rat coronary and mesenteric arterial bed perfusates.
TLDR
Different BK-processing pathways operate in the perfusates of rat MAB and coronary bed, with a substantial participation of a des-Arg(9)-BK-forming enzyme identical to rat pancreatic carboxypeptidase B (CPB). Expand
The Effect of Acute Angiotensin-Converting Enzyme and Neutral Endopeptidase 24.11 Inhibition on Plasma Extravasation in the Rat
TLDR
It is shown that ACE inhibitor-induced plasma extravasation is enhanced by concomitant inhibition of NEP, and this study is the first to relate the degree of ACE and/or NEP inhibition toextravasation liability in the rat model. Expand
Neprilysin Inhibitors and Bradykinin
TLDR
The approval of LCZ696 therapy for HFrEF represents the first approval of long-term neprilysin inhibitor administration, and it remains to be seen whether LCZ637 therapy for other conditions such as hypertension is also accompanied by an acceptable incidence of angioedema. Expand
The therapeutic potential of bradykinin B2 receptor agonists in the treatment of cardiovascular disease
  • H. Heitsch
  • Medicine
  • Expert opinion on investigational drugs
  • 2003
TLDR
BK B2 receptor agonists may have important clinical value in the treatment and prevention of various cardiovascular disorders such as hypertension, ischaemic heart disease, left ventricular hypertrophy, ventricular remodelling and congestive heart failure as well as diabetic disorders by mimicking the reported beneficial effects of BK. Expand
Structure based inhibitor design studies on angiotensin converting enzyme homologues
TLDR
AnCE, an ACE homologue from Drosophila melanogaster, has been used as a model to study the structural basis of ACE inhibition by a number of different inhibitory peptides, highlighting how interactions with active site residues could be exploited in the development of new, domain selective, inhibitors. Expand
Putative roles of kinin receptors in the therapeutic effects of angiotensin 1-converting enzyme inhibitors in diabetes mellitus.
TLDR
The Janus-faced of kinin receptors needs to be taken into account in future drug development, and locally acting kinin B(1)/B(2) receptor agonists if used in a safe therapeutic window may represent a more rationale strategy in the prevention and management of diabetic complications. Expand
Production of soluble Neprilysin by endothelial cells.
TLDR
The data indicated for the first time that NEP is released from endothelial cells via exosomes, and that this process is dependent on ADAM-17. Expand
A cysteine-type carboxypeptidase, cathepsin X, generates peptide receptor agonists.
TLDR
It is reported that a cysteine-type carboxypeptidase, cathepsin X, is able to modulate the kallikrein-kinin system through carboxyterminal processing of the small peptide hormones bradykinin and kallidin. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 30 REFERENCES
Kallidin- and bradykinin-degrading pathways in human heart: degradation of kallidin by aminopeptidase M-like activity and bradykinin by neutral endopeptidase.
TLDR
In human cardiac membranes, the most critical step in kinin metabolism, that is, inactivation of BK, appears to be mediated mostly by NEP, which suggests a role for NEP in the local control of Bk concentration in heart tissue. Expand
The degradation of bradykinin (BK) and of des-Arg9-BK in plasma.
The metabolism of bradykinin (BK), des-Arg9-BK, and two analogues of the latter was studied in human, rat, and rabbit plasma, using bioassays and high pressure liquid chromatography (HPLC) forExpand
Hydrolysis of Bradykinin by Angiotensin‐Converting Enzyme
TLDR
It is concluded that one enzyme, acting as a dipeptidyl carboxypeptidase, catalyzes both the conversion of angiotensin I to angiotENSin II and the hydrolysis of bradykinin. Expand
Intravascular and interstitial degradation of bradykinin in isolated perfused rat heart
TLDR
Only interstitial, but not intravascular concentrations of BK are increased by kininase inhibitors to the extent that a significant potentiation of Bk effects could be explained. Expand
Mechanism of digestion of bradykinin and lysylbradykinin (kallidin) in human serum. Role of carboxypeptidase, angiotensin-converting enzyme and determination of final degradation products.
TLDR
The studies indicate that the final products of bradykinin degradation were the tripeptide Arg-Pro-Pro, one mole each of Ser, Pro, Gly, and Arg, and two moles of phenylalanine. Expand
Serum interspecies differences in metabolic pathways of bradykinin and [des-Arg9]BK: influence of enalaprilat.
TLDR
Striking species differences in the serum metabolism of kinins are revealed that could address at least partially some of the controversial data related to the cardioprotective role of Kinins. Expand
SCH 39370, a neutral metalloendopeptidase inhibitor, potentiates biological responses to atrial natriuretic factor and lowers blood pressure in desoxycorticosterone acetate-sodium hypertensive rats.
TLDR
The results suggest that NEP can play a role in ANF disposition in vivo and that potentiation of the biological activities of high doses of ANF by SCH 39370 may be consequent to its inhibitory effect on ANF degradation. Expand
Effects of aminopeptidase P inhibition on kinin-mediated vasodepressor responses.
TLDR
It is concluded that in the rat AMP contributes to regulation of BK metabolism and responses and in rats with aortic coarctation hypertension, the acute antihypertensive effects of Aps plus Lis were greater than Lis alone. Expand
Studies on the induction of pharmacological responses to des‐Arg9‐bradykinin in vitro and in vivo
TLDR
It has been demonstrated that LPS induces B 1‐receptors in rabbits enabling des‐Arg9‐Bk to act as a hypotensive agent and the development of responses mediated by the B1‐receptor in the two experimental systems seems to be unrelated to the activation of neutrophil leukocytes, but may be related to theactivation of tissue macrophages. Expand
Bradykinin peptides in kidney, blood, and other tissues of the rat.
TLDR
Tissue levels of bradykinin peptides are much higher than circulating levels, consistent with their formation at a local tissue site, and it is demonstrated that T-kininogen makes no detectable contribution to renal or circulating brady Kininin peptide levels. Expand
...
1
2
3
...